Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
Phase 3 data show Bausch + Lomb's LUMIFY Preservative Free eye drops are as safe and effective as the original LUMIFY in reducing ocular redness
The multicenter study with 380 participants confirmed that LUMIFY Preservative Free eye drops are non-inferior in efficacy to the original LUMIFY and have a favorable safety profile, offering an effective preservative-free option for sensitive eyes
LUMIFY delivers noticeable results in one minute, lasts up to eight hours and is the No. 1 doctor-recommended redness reliever brand; more info at www.lumifyeyes.com
Article content
VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Ophthalmology and Therapy has published results from a phase 3 study which assessed the efficacy and safety of LUMIFY Preservative Free redness reliever eye drops compared to LUMIFY redness reliever eye drops for reducing ocular redness.
Article content
'Since launching in 2018, LUMIFY has been the No. 1 doctor-recommended redness reliever brand, known for delivering noticeable results in one minute and lasting up to eight hours,' 1 said John Ferris, president, Consumer, Bausch + Lomb. 'This study demonstrates that our new LUMIFY Preservative Free eye drops reduce redness quickly and are just as safe and effective as the original LUMIFY, providing a needed option for patients with eye sensitivities.'
Article content
In the randomized, active-controlled, multicenter study, 380 participants with ocular redness received either LUMIFY Preservative Free or LUMIFY, administered as a single drop four times daily for four weeks. The primary objective was to demonstrate that LUMIFY Preservative Free is non-inferior to LUMIFY in reducing ocular redness. The primary efficacy endpoint was investigator-assessed ocular redness score at eight timepoints from five-minutes to 240-minutes after drop administration on day one. The secondary objective of the study was to compare the safety of LUMIFY Preservative Free and LUMIFY.
Article content
The study met its primary objective, confirming that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing ocular redness in adults. A day one analysis of all 11 time points (one minute to 480 minutes post-administration) further supported these findings; and additional secondary efficacy endpoint data from one minute, 360 minutes and 480 minutes post-administration demonstrated that LUMIFY Preservative Free performs similarly to LUMIFY. The overall safety profile of LUMIFY Preservative Free was favorable and comparable to LUMIFY, and the occurrence of ocular treatment-emergent adverse events was similar in both treatment groups. In this clinical trial, LUMIFY Preservative Free demonstrated to have a low incidence of side effects, like rebound redness and loss of efficacy over time, when used as directed.
Article content
'The results show that LUMIFY Preservative Free is a well-tolerated alternative option for consumers with ocular redness who have sensitivities to preservatives or are at increased risk of ocular surface disease,' said Melissa Toyos, MD, and partner, Toyos Clinic, Nashville, TN.
Article content
About the LUMIFY Brand
Article content
The LUMIFY brand began in 2018 with the U.S. launch of LUMIFY redness reliever eye drops. Before LUMIFY, redness relievers relied on the same ingredients for decades and were associated with well-known side effects. LUMIFY and LUMIFY Preservative Free are the only over-the-counter redness relievers formulated with low-dose brimonidine tartrate 0.025% that selectively target eye redness and offer excellent results with a lower risk of rebound redness and loss of efficacy when used as directed. In 2023, Bausch + Lomb introduced LUMIFY EYE ILLUMINATIONS™, a line of specialty eye care products specifically developed for the sensitive area around the eyes. In June 2025, Bausch + Lomb launched LUMIFY Preservative Free eye drops in the U.S. For more information on the LUMIFY brand, visit
Article content
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit
Article content
Article content
,
Article content
Article content
,
Article content
Article content
,
Article content
X
Article content
and
Article content
YouTube
Article content
.
Article content
References
Article content
©2025 Bausch + Lomb.
Article content
LUM.0127.USA.25
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contact:
Article content
Article content
Kristy Marks
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
Alleged drug deals from chair outside Victoria consumption site ‘unacceptable,' police chief says
Victoria Police Chief Del Manak speaks during a press conference in Victoria, on Wednesday, March 24, 2021. THE CANADIAN PRESS/Chad Hipolito Victoria's police chief says undercover operatives didn't have to look far to find evidence of criminality outside a safe consumption site in the city. A suspected cocaine dealer was selling drugs from a chair set up directly in front of the overdose prevention facility, Chief Del Manak said. The chief said in an interview on Thursday that he called senior leadership at the Island Health authority to express disappointment over the handling of the suspect, who allegedly sold the drug twice to undercover officers and was arrested. Manak said he supports an overdose consumption site in the city, but it was 'unacceptable' that a service provider from the facility on Pandora Ave. was seen to 'do nothing' about the man. 'That's disturbing, and it's extremely disappointing for me to see that a staff member would do (nothing),' Manak said. An employee at the facility had a 'rapport' with the alleged dealer, interacted with the person and turned a 'blind eye' to the alleged trafficking, the chief said. He said the service provider 'obviously' had a relationship with the alleged dealer, while a police news release said the man had 'a consistent flow of customers.' 'Officers initiated two separate purchases from the man and notably observed a service provider from the facility interacting with him without any apparent concern for the illegal activity,' the release said. Manak said Island Health told him it would be addressing his concerns through training and a policy review to make sure that the facility operates in co-operation with community partners, including the Victoria Police Department. Island Health told The Canadian Press it was aware of arrests on Pandora Ave. 'and we are thankful for the brave and tireless work our law enforcement partners do every day.' It said that mitigating street disorder could include operators 'building relationships with the community,' keeping those waiting for services calm and orderly, de-escalating aggression, encouraging people to pack up encampments in front of services, and 'asking people to not actively deal.' 'These requests are based on relationships and trust and are not enforceable,' it said. Manak said instead of interacting with the alleged dealer, the service provider should have called police. He said he did not expect the worker to confront the man. 'I'm asking, 'where is your sense of duty and responsibility for even the people accessing your site to see that there's a drug trafficker setting up shop at your front doors?'' Manak said. He added that it is the 'sole responsibility' of his department to target drug traffickers and criminality at large. But it is 'problematic' when drug trafficking is happening in front of a safe consumption site. 'Then you have a staff member connected to the location coming out and engaging with this individual,' Manak said. 'From there, the health authority cannot turn a blind eye, and they need to be responsive in phoning the police.' Everybody, including service providers, have a 'duty and responsibility' to stop street disorder, Manak said. Manak said his department has a 'very good working relationship' with Island Health, adding it supports the safe consumption site and the concept behind it. 'It offers support for individuals who are addicted to illicit drugs, and this is a much needed service,' he said. The chief said he's treating the incident as a 'one-off,' and is confident that Island Health will address this issue. The facility is located in the 900-block of Pandora Ave., in an area where homeless people have set up tents and other sleeping structures and crime has been a recurring problem. Bicycles and shopping carts loaded with belongings are parked nearby. Portable fencing has been set up to separate encampments from a nearby church and other businesses. Victoria recently announced more than $10 million for more police and bylaw officers and other measures to reduce crime, homelessness and addiction. One city councillor submitted a recent motion to shut down the supervised consumption site, but council deferred request to later this year. Manek said that would be a mistake. 'If we shut down supervised consumption sites, people are going to continue to use illicit drugs,' he said. 'We know that the supervised consumption site is saving lives, but again, to shut down is not the right step.' This report by Wolfgang Depner, The Canadian Press, was first published July 31, 2025.
CBC
3 hours ago
- CBC
Gaza aid seeker deaths continue despite international pressure
Gaza's Hamas-run Health Ministry says dozens have been killed near aid trucks within 24 hours, even as countries including Canada increase pressure to address the growing starvation crisis.
CTV News
3 hours ago
- CTV News
Ontario reports 54 new measles cases
Ontario reports 54 new measles cases, including 40 in the Sudbury district tied to private gatherings. The province has now recorded 2,352 cases since October, mostly in unvaccinated individuals, according to health officials.
